International Journal of Fertility and Sterility
November 9, 2020
Nadia Hossein-Zadeh, Morteza Bagheri, Isa Abdi Rad et al.
Background: 3,4-Methylenedioxymethamphetamine (MDMA) disrupts function of the endocrine system and differentorgans such as heart, blood vessels, kidney, liver and nervous systems. This study was conducted to evaluateimpact of MDMA on apoptosis and Zinc in the MDMA-induced apoptosis of cultured Sertoli cells by measuringCaspase-3 gene expression.Materials and Methods: In this experimental study,...
History of psychology
November 1, 2020
Matei Iagher
This article aims at placing Henri Delacroix's (1908) book on the psychology of mysticism in the context of debates in the psychology of religion in the earlier part of the 20th century. I argue that Delacroix's work was authored as part of a wider debate that Delacroix maintained with the American school of the psychology of religion regarding the role of emotions in religious experience. As I...
Substance Use & Misuse
October 24, 2020
Balthazar Bazin, David Duroy, Michel Lejoyeux
27 citations
3,4-Methylenedioxy-N-methylamphetamine (MDMA) is increasing being used by youth in Europe and in France, but characteristics of its use are unknown. Objectives: The aim was to characterize MDMA use in a sample of French medical students. Methods: Cross-sectional study of Paris VII medical students (N = 592) with an online self-reporting questionnaire. Results: 592 students completed the online...
PLoS One
October 14, 2020
Elliot Marseille, J. Kahn, B. Yazar-Klosinski et al.
55 citations
Background Chronic posttraumatic stress disorder (PTSD) is a disabling condition that generates considerable morbidity, mortality, and both medical and indirect social costs. Treatment options are limited. A novel therapy using 3,4-methylenedioxymethamphetamine (MDMA) has shown efficacy in six phase 2 trials. Its cost-effectiveness is unknown. Methods and findings To assess the...
Journal of Psychopharmacology
October 8, 2020
Yasmin Schmid, Peter Gasser, Peter Oehen et al.
82 citations
Background: Lysergic acid diethylamide (LSD) and 3,4-methylenedioxymethamphetamine (MDMA) were used in psychotherapy in the 1960s–1980s, and are currently being re-investigated as treatments for several psychiatric disorders. In Switzerland, limited medical use of these substances is possible in patients not responding to other treatments (compassionate use). Methods: This study aimed to...
Our Love Affair with Drugs
October 1, 2020
Jerrold C Winter
Abstract As these words are written, the chemical we will call MDMA is a Schedule I drug. This means that MDMA (a) has no currently accepted medical use, (b) no currently accepted safety even under medical supervision, and (c) has a high potential for abuse. On the other hand, there are those who see great therapeutic potential in MDMA, and the Food and Drug Administration (FDA) has designated...
Farmacja Polska
September 28, 2020
Agata Tadeja
1 citation
Research on using drugs in medicine was almost completely stopped and delegalized in 1971, by Convention on Psychotropic Substances. Most of studies carried out before 1971 were methodologically inappropriate according to current research methodologies, yet it was proven that there is some potential in using substances like lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine,...
Expert Review of Neurotherapeutics
September 21, 2020
Hartej Gill, Barjot Gill, David C J Chen-Li et al.
62 citations
Psychedelics, such as psilocybin and MDMA, offer an alternative avenue of therapy for many mental health disorders. Available evidence indicates that psychedelics may offer a single-dose, rapid effect model that have robust effects with treatment-resistant mental disorders and a unique advantage as a possible monotherapy for mental illness. Novel clinical trials that evaluate the safety,...
Journal of Psychoactive Drugs
September 15, 2020
Tracey Varker, Loretta Watson, Kari Gibson et al.
57 citations
The aim of this systematic review was to examine the efficacy of MDMA, ketamine, LSD, and psilocybin for the treatment of posttraumatic stress disorder (PTSD). A search of four databases for English language, peer-reviewed literature published from inception to 18th October 2019 yielded 2,959 records, 34 of which were screened on full-text. Observational studies and RCTs which tested the...
Journal of Psychopharmacology
September 10, 2020
H. Oeri
42 citations
The last two decades have seen a revival of interest in the entactogen 3,4-methylenedioxy-N-methylamphetamine (MDMA) as an adjunct to psychotherapy, particularly for the treatment of post-traumatic stress disorder. While clinical results are highly promising, and MDMA is expected to be approved as a treatment in the near future, it is currently the only compound in its class of action that is...